Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
milatuzumab hla-dr antigens-associated invariant NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Lymphocytic Leukemia[MeSHID:D015451]
Lupus Erythematosus
Systemic[MeSHID:D008180]		 318.26 phase 1/2 antibody
milatuzumab hla-dr antigens-associated invariant NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Lymphocytic Leukemia[MeSHID:D015451]
Lupus Erythematosus
Systemic[MeSHID:D008180]		 318.26 phase 1/2 unknown
milatuzumab hla-dr antigens-associated invariant NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Chronic Lymphocytic Leukemia[MeSHID:D015451]
Lupus Erythematosus
Systemic[MeSHID:D008180]		 318.26 phase 1/2 antagonist
click here to return to the previous page